Literature DB >> 22139404

Estrogen therapy initiated at an early age increases bone mineral density in Turner syndrome patients.

Michiko Kodama1, Hiroko Komura, Takahiro Kodama, Yukihiro Nishio, Tadashi Kimura.   

Abstract

Patients with Turner syndrome (TS) almost develop osteoporosis, resulting from chromosomal deficiency and estrogen deficiency by gonadal dysgenesis. The aim of this study was to assess bone mineral density (BMD) during continuous estrogen therapy in young TS patients by measuring lumbar spine BMD of 67 TS patients using dual-energy X-ray absorptiometry. Twenty-seven patients who were treated with adult-doses of estrogen prior to the first evaluation, exhibited a significantly higher initial BMD than 30 patients treated with low-dose estrogen therapy and 10 patients without estrogen therapy (0.808 g/cm², 0.714 g/cm², and 0.664 g/cm², respectively). During continuous adult-dose estrogen therapy, BMD significantly increased in each group (maximum BMD during the study, 0.842 g/cm², 0.790 g/cm², and 0.724 g/cm², respectively). Initial and maximum BMD showed significant negative correlation with the age at which adult-dose estrogen therapy was initiated (r = -0.57 and -0.45, respectively). Among the patients not treated with adult-dose estrogen therapy prior to the first evaluation, the annual increase in the rate and amount of BMD was significantly higher when adult-dose estrogen therapy was initiated before age 18 (rate, 4.4 % before age 18 vs. 3.1 % after age 18; amount, 0.03 g/cm² before age 18 vs. 0.02 g/cm² after age 18). In summary, estrogen therapy increased BMD in young TS patients and might be more effective if initiated by age 18.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22139404     DOI: 10.1507/endocrj.ej11-0267

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  5 in total

Review 1.  Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with turner syndrome: a systematic review and meta-analysis.

Authors:  Dahima Cintron; Rene Rodriguez-Gutierrez; Valentina Serrano; Paula Latortue-Albino; Patricia J Erwin; Mohammad Hassan Murad
Journal:  Endocrine       Date:  2016-07-29       Impact factor: 3.633

Review 2.  Current Understanding of the Etiology, Symptomatology, and Treatment Options in Premature Ovarian Insufficiency (POI).

Authors:  Bunpei Ishizuka
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-25       Impact factor: 5.555

3.  Prepubertal ultra-low-dose estrogen therapy is associated with healthier lipid profile than conventional estrogen replacement for pubertal induction in adolescent girls with Turner syndrome: preliminary results.

Authors:  Anna Ruszala; Malgorzata Wojcik; Agata Zygmunt-Gorska; Dominika Janus; Joanna Wojtys; Jerzy B Starzyk
Journal:  J Endocrinol Invest       Date:  2017-04-10       Impact factor: 4.256

Review 4.  HRT for women with premature ovarian insufficiency: a comprehensive review.

Authors:  Lisa Webber; Richard A Anderson; Melanie Davies; Femi Janse; Nathalie Vermeulen
Journal:  Hum Reprod Open       Date:  2017-07-12

5.  Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome.

Authors:  M Chiarito; L Piacente; N Chaoul; P Pontrelli; G D'Amato; A Grandone; G Russo; M E Street; M G Wasniewska; G Brunetti; M F Faienza
Journal:  J Endocrinol Invest       Date:  2022-03-02       Impact factor: 5.467

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.